Your browser doesn't support javascript.
loading
Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.
Velentzis, Louiza S; Smith, Megan A; Simms, Kate T; Lew, Jie-Bin; Hall, Michaela; Hughes, Suzanne; Yuill, Susan; Killen, James; Keane, Adam; Butler, Katherine; Darlington-Brown, Jessica; Hui, Harriet; Brotherton, Julia M L; Skinner, Rachel; Brand, Alison; Roeske, Lara; Heley, Stella; Carter, Jonathan; Bateson, Deborah; Frazer, Ian; Garland, Suzanne M; Guy, Rebecca; Hammond, Ian; Grogan, Paul; Arbyn, Marc; Castle, Philip E; Saville, Marion; Armstrong, Bruce K; Canfell, Karen.
Afiliação
  • Velentzis LS; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: louizav@nswcc.org.au.
  • Smith MA; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, University of Sydney, NSW, Australia.
  • Simms KT; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Australia.
  • Lew JB; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Australia.
  • Hall M; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Australia.
  • Hughes S; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
  • Yuill S; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
  • Killen J; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
  • Keane A; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
  • Butler K; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
  • Darlington-Brown J; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
  • Hui H; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
  • Brotherton JML; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Victorian Cytology Service Ltd, Carlton, Victoria, Australia.
  • Skinner R; Discipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia; Children's Hospital Westmead, Westmead, NSW, Australia.
  • Brand A; Discipline of Obstetrics, Gynaecology and Neonatology, Westmead Clinical School, University of Sydney, NSW, Australia; Department of Gynaecological Oncology, Westmead Hospital, Westmead, NSW, Australia.
  • Roeske L; Victorian Cytology Service Ltd, Carlton, Victoria, Australia.
  • Heley S; Victorian Cytology Service Ltd, Carlton, Victoria, Australia.
  • Carter J; Chris O'Brien Lifehouse, Sydney, NSW, Australia.
  • Bateson D; Family Planning NSW, NSW, Australia; Sydney Medical School, Discipline of Gynaecology & Neonatology, University of Sydney, NSW, Australia.
  • Frazer I; The University of Queensland Diamantina Institute, Queensland, Australia.
  • Garland SM; Department of Microbiology & Infectious Diseases, Royal Women's Hospital, Parkville, Victoria, Australia; Murdoch Children's Research Institute, 50 Flemington Road, Parkville, 3052, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville 3052, Victoria, Australia.
  • Guy R; Kirby Institute, University of NSW, Sydney, NSW, Australia.
  • Hammond I; Division of Obstetrics and Gynaecology, University of Western Australia, Perth, Australia.
  • Grogan P; Cancer Council Australia, Sydney, NSW, Australia.
  • Arbyn M; Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.
  • Castle PE; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, USA.
  • Saville M; Victorian Cytology Service Ltd, Carlton, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville 3052, Victoria, Australia.
  • Armstrong BK; School of Public Health, University of Sydney, NSW, Australia; School of Population and Global Health, University of Western Australia, Perth, Australia.
  • Canfell K; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, University of Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Australia.
Gynecol Oncol ; 152(3): 465-471, 2019 03.
Article em En | MEDLINE | ID: mdl-30876490
OBJECTIVE: Australia's HPV vaccination and HPV-based cervical screening programs are changing the landscape in cervical cancer prevention. We aim to identify areas which can make the biggest further impact on cervical cancer burden. This protocol describes the first stage of a program of work called Pathways-Cervix that aims to generate evidence from modelled evaluations of interventions across the cervical cancer spectrum. METHODS: Based on evidence from literature reviews and guidance from a multi-disciplinary Scientific Advisory Committee (SAC), the most relevant evaluations for prevention, diagnosis and treatment were identified. RESULTS: Priority evaluations agreed by the SAC included: increasing/decreasing and retaining vaccination uptake at the current level; vaccinating older women; increasing screening participation; methods for triaging HPV-positive women; improving the diagnosis of cervical intraepithelial neoplasia (CIN) and cancer; treating cervical abnormalities and cancer; and vaccinating women treated for CIN2/3 to prevent recurrence. Evaluations will be performed using a simulation model, Policy1-Cervix previously used to perform policy evaluations in Australia. Exploratory modelling of interventions using idealised scenarios will initially be conducted in single birth cohorts. If these have a significant impact on findings then evaluations with more realistic assumptions will be conducted. Promising strategies will be investigated further by multi-cohort simulations predicting health outcomes, resource use and cost outcomes. CONCLUSIONS: Pathways-Cervix will assess the relative benefits of strategies and treatment options in a systematic and health economic framework, producing a list of 'best buys' for future decision-making in cervical cancer control.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Erradicação de Doenças / Modelos Teóricos Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Erradicação de Doenças / Modelos Teóricos Idioma: En Ano de publicação: 2019 Tipo de documento: Article